Clinical Trial Update: Pre-operative Nivolumab and Ipilimumab, Followed by Post-operative Nivolumab, for MSI/dMMR Oeso-gastric Adenocarcinoma. [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating pre-operative nivolumab and ipilimumab followed by postoperative nivolumab in localized MSI/dMMR esophagogastric adenocarcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophagogastric Adenocarcinoma

Drugs mentioned

• OPDIVO (nivolumab)
• Yervoy (ipilimumab)

Snippet

Sponsor: GERCOR - Multidisciplinary Oncology Cooperative Group | Conditions: Localized Oesogastric Adenocarcimona, MSI and or dMMR | Phase 2 | Status: ACTIVE_NOT_RECRUITING